Understanding the Needs of Migraine Patients
Tóm tắt
Although migraine is a highly disabling disorder, it remains underdiagnosed. Its relevance is often minimized by both patients and physicians, and the presence of concomitant diseases such as depression can interfere with diagnosis. Migraine is often inappropriately treated by patients who often self-administer over-the-counter analgesics or do not follow physician prescriptions, and by physicians who do not always prescribe migraine-specific treatments when they are indicated. These factors can lead to patient dissatisfaction with migraine therapy. Surveys show that migraine patients consider complete pain relief to be the most important attribute of an acute migraine treatment. Other important attributes are rapid onset, lack of recurrence, restoration of function, and the absence of side-effects. Medical professionals treating migraine need up-to-date clinical information to diagnose this disorder effectively, to understand the breadth of treatments available, and to choose the most appropriate treatment. Physician-patient communication is also a key factor in migraine management and allows physicians to gain the trust of their patients. Educating patients about migraine and involving them in treatment decisions are likely to improve patient satisfaction with therapy. Education and involvement will also help patients to understand their disorder better, to identify and avoid migraine triggers, and to improve their understanding of and compliance with drug therapy. Such an approach may also help physicians to manage patient expectations.
Tài liệu tham khảo
Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001; 17 suppl. 1: S4–12
Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study 2001; 41: 646–657.
Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000; 57: 418–20
Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614–24
Goadsby PJ. Serotonin receptors and the acute attack of migraine. Clin Neurosci 1998; 5: 18–23
Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668–75
Goadsby PJ. Advances in the pharmacotherapy of migraine How knowledge of pathophysiology is guiding drug development. Drugs R D 1999; 2: 361–674
Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/1D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000; 55 suppl. 2: S8–14
Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002; 59: 1084–8
Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131–7
Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs — a nation-wide population-based survey in Sweden. Cephalalgia 2004; 24: 455–65
Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60: 441–8
Lucas C, Chauffaut C, Artaz MA, et al. FRAMIG 2000; medical and therapeutic management of migraine in France. Cephalalgia 2004; 25: 267–79
MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey. Headache 2003; 43: 19–26
Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259–87
Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication — a review. Cephalalgia 2004; 24: 321–32
Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638–45
Lipton RB, Liberman J, Cutrer FM, et al. Treatment preferences and the selection of acute migraine medications: results from a population-based survey. J Headache Pain 2004; 5: 123–30
Lipton RB, Cutrer FM, Goadsby PJ, et al. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine patients, neurologists, and primary care physicians. Curr Med Res Opin 2005; 21: 413–24
Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39 suppl. 2: S20–6
Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20: 554–60
Edmeads J. Communication issues in migraine diagnosis. Can J Neurol Sci 2002; 29 suppl. 2: S8–10
Gallagher RM, Alam R, Shah S, et al. Headache in medical education: medical schools, neurology and family practice residencies. Headache 2005; 45: 866–73
Carr-Hill R, Jenkins-Clarke S, Dixon P, et al. Do minutes count? Consultation lengths in general practice J Health Serv Res Policy 1998; 3: 207–13
Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992; 12: 221–8
Lipton RB, Cady RK, Stewart WF, et al. Diagnostic lessons from the Spectrum Study. Neurology 2002; 58 suppl. 6: S27–31
Silberstein SD. Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache 2001; 41 suppl. 1: S11–7
Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the landmark study. Headache 2004; 44: 856–64
Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine Validation Study. Neurology 2003; 61: 375–82
Cady RK, Borchert LD, Spalding W, et al. Simple and efficient recognition of migraine with a 3-question headache screen. Headache 2004; 44: 323–7
Holmes WF, MacGregor EA, Sawyer JP, Lipton RB. Information about migraine disability influences physicians’ perceptions of illness severity and treatment needs. Headache 2001; 41: 343–50
Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 2001; 56 suppl. 1: S20–8
Bjorner JB, Kosinski M, Ware JE. Calibration of an item pool for assessing the burden of headaches: an application of item response theory to the headache impact test (HIT). Qual Life Res 2003; 12: 913–33
Dowson AJ. Assessing the impact of migraine. Curr Med Res Opin 2001; 17: 298–309
Stewart SW, Lipton RB, Simon D, et al. Validity of an illness severity measure for headache in a population sample of migraine patients. Pain 1999; 79: 291–301
Stewart SW, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache patients. Cephalalgia 1999; 19: 107–14
Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 2000; 40: 204–15
Jacobson GP, Ramadan NM, Norris L, et al. Headache Disability Inventory: short-term test-retest reliability and spouse perceptions. Headache 1999; 35: 534–9
Pryse-Phillips W. Evaluating migraine disability: the headache impact test instrument in context. Can J Neurol Sci 2002; 29 suppl. 2: S11–5
Kurtz SM. Doctor-patient communication: principles and practices. Can J Neurol Sci 2002; 29 suppl. 2: S23–9
Chabriat H, Danchot J, Michel P, et al. Precipitating factors of headache: a prospective study in a national control-matched survey in migraineurs and nonmigraineurs. Headache 1999; 39: 335–8
Baos V, Ester F, Castellanos A, et al. Use of a structured migraine diary improves patient and physician communication about migraine disability and treatment outcomes. Int J Clin Pract 2005; 59: 281–6